EGFR and non-small cell lung carcinoma: Significant extended survival was observed in patients with advanced NSCLC harboring EGFR mutations treated with EGFR tyrosine kinase inhibitors (TKIs), establishing these inhibitors as the frontline treatment for patients with compatible mutations [3].